RT Journal Article
SR Electronic
T1 Evaluate the potential of IP-10 as biomarker for the MDR-TB treatment outcome
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2785
VO 42
IS Suppl 57
A1 Yi-Wen Huang
A1 Hsin-Chieh Tsai
A1 Chia-Ming Chen
A1 Ya-Yen Yu
A1 Gwan-Han Shen
A1 Wen-Ta Yang
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2785.abstract
AB IntroductionInterferon gamma inducible protein-10 (IP-10) has been suggested as an alternative marker to diagnose TB recently. A higher level of IP-10 was observed in antigen or mitogen stimulated TB blood samples. Increased IP-10 activity in response to TB specific antigens in TB patients has also been observed to decrease after successful therapy. This study aims to evaluate the potential of IP-10 values to be used as biomarkers to assess MDR-TB treatment.MethodsThis study recruited a total of 67 patients including 20 tuberculosis (TB), 17 multi-drug resistant tuberculosis (MDR-TB) and 30 healthy cases (HC). Blood samples were taken from each subject to measure the IP-10 values at the beginning of the experiment and at 2 weeks, 2 months and 6 months after treatment. The values were compared with the sputum results to evaluate changes in antigen values during treatment.ResultsHigher levels of IP-10 and TB antigen were observed in the TB (458.7±301.9pg/ml, 2.1pg/ml) and the MDR-TB groups (513.7±279.8pg/ml, 1.6pg/ml) than the HC case (131.9±102.8pg/ml, 0.4pg/ml). However, no regular patterns were found for the changes in TB antigen or IP-10 values in the two treatment groups. Nevertheless, after 6 months of anti-TB treatment, significant decrease in IP10 values was noted in both the TB (271.7±254.5pg/ml) and MDR-TB (303.6±273.7pg/m) groups. In addition, the IP-10 levels and the TB antigen values were lower when sputum smear and culture were negative as compared to when both were positive.ConclusionA single IP-10 value cannot be used as a biomarker to confirm sputum conversion, however, the IP-10 value can assist to detect a higher risk tuberculosis group and be used to assess treatment outcome.